



Supplementary Information:

**The tyrosine phosphatase SHP2 controls TGF β -induced
STAT3 signaling to regulate fibroblast activation and fibrosis**

Zehender et al.




Supplementary Figure 1: Decreased expression of SHP2 in experimental skin fibrosis. a: Decreased expression of Shp2 and reduced mRNA levels of *Shp2* in the skin of mice challenged with bleomycin ($n \geq 5$). Representative HE images and immunofluorescence staining of SHP2, vimentin and DAPI shown at 200- and 600-fold magnification. Horizontal scale bar, 500 μm . Voronoi tessellated pictures and histograms of respective Immunofluorescence signals are included. **b:** Reduced mRNA levels of *Shp2* in TSK1 mice (2 mg tamoxifen over 5 days) ($n \geq 7$). Representative images stained for SHP2, vimentin and DAPI shown at 200- and 600-fold magnification. Results shown are representative of a minimum of two independent experiments per model. All data are presented as median \pm s.e.m. The p-values are expressed as follows: $0.05 > p > 0.01$ as *; $0.01 > p > 0.001$ as **; $p < 0.001$ as ***; ns= not significant. Significance was determined by Mann–Whitney test. NSC-87877= SHP1/SHP2 inhibitor; TSK1= Tight skin; Pa/Pa= Tight skin control; Bleo= Bleomycin.




Supplementary Figure 2: Inhibition of Shp2 by NSC-87877 (100 μ M), SHP099 (1.4 μ M) and 11-a1 (0.2 μ M) inhibitors in cultured dermal fibroblasts. a: mRNA levels of *Colla1* and *Acta2* (n = 5). b-c: Representative immunofluorescence staining of α SMA, Stress fibers and DAPI shown at 400-fold magnification (b) with quantification (c). Horizontal scale bar, 500 μ m. Results shown are representative of three independent experiments. All data are presented as median \pm s.e.m. The p-values are expressed as follows: $0.05 > p > 0.01$ as *; $0.01 > p > 0.001$ as **; $p < 0.001$ as *; ns= not significant. Significance was determined by Mann–Whitney test. NSC-87877, SHP099 and 11-a1 are SHP1/SHP2 inhibitor; unst.= unstimulated.**






a



Supplementary Figure 3: a: Treatment with NSC-87877 does not modify the metabolic activity in resting fibroblasts, but prevents the increase induced by TGFβ. Results shown are representative of two independent experiments (n = 4). All data are presented as median ± s.e.m. The p-values are expressed as follows: 0.05 > p > 0.01 as *; 0.01 > p > 0.001 as **; p < 0.001 as ***; ns= not significant. Significance was determined by Mann–Whitney test. NSC-87877= SHP1/SHP2 inhibitor; MTT= tetrazolium dye.



Supplementary Figure 4: Schematic summary of the proposed role of SHP2 in TGFβ-dependent fibroblast activation (a) and of the effects of SHP2-inhibitors (b). The Figure was created by the authors using in part images from Servier Medical Art, licensed under a Creative Common Attribution 3.0 Generic License. <http://smart.servier.com/>. P= Phosphorylation



Supplementary Figure 5: Uncropped scan of Original Western blots.

Figure 7e





Figure 8d



Supplementary Figure 6: Uncropped scan of Original Western blots.

Supplementary Table 1: primers

human β -ACTIN forward	5'-AGA AAA TCT GGC ACC ACA CC-3'
human β -ACTIN reverse	5'-TAG CAC AGC CTG GAT AGC AA-3'
human SHP2 forward	5'-TAT CCT CTG AAC TGT GCA GAT CC-3'
human SHP2 reverse	5'-TCT GGC TCT CTC GTA CAA GAA AA-3'
human COL1A1 forward	5'-ACG AAG ACA TCC CAC CAA TC-3'
human COL1A1 reverse	5'- ATG GTA CCT GAG GCC GTT C-3'
human ACTA2 forward	5'-TGG GCT GAA GCG CAC TGA CC-3'
human ACTA2 reverse	5'- CCG CGG CTC TTG CCC ACA T-3'
murine β -actin forward	5'-TCT TTG ATG TCA CGC ACG AT-3'
murine β -actin reverse	5'-TAC AGC TTC ACC ACC ACA-3'
murine shp2 forward	5'-GGA GAG CAT CGT GGA TGC-3'
murine shp2 reverse	5'-TCC CAG CGC TGC AGT GAA-3'
murine Acta2 forward	5'-ATG CCT CTG GAC GTA CAA CTG-3'
murine Acta2 reverse	5'-CAC ACC ATC TCC AGA GTC CA-3'